Advisory Research Inc Xenon Pharmaceuticals Inc. Transaction History

Advisory Research Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$34.16 - $39.73 $208,239 - $242,194	-6,096 Reduced 13.72%	38,326 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$34.84 - $43.54 $612,556 - $765,520	17,582 Added 65.51%	44,422 $1.71 Million
Q1 2023 May 12, 2023	SELL	$33.46 - $40.35 $197,112 - $237,701	-5,891 Reduced 18.0%	26,840 $960,000
Q4 2022 Feb 13, 2023	SELL	$33.06 - $39.43 $122,553 - $146,167	-3,707 Reduced 10.17%	32,731 $1.29 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $44,276 - $57,261	1,438 Added 4.11%	36,438 $1.32 Million
Q2 2022 Aug 17, 2022	BUY	$25.44 - $35.16 $890,400 - $1.23 Million	35,000 New	35,000 $1.06 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.